Sign In
Buy AFMD
$0.182
+0 (+0%)
At Close: Sep 16, 2025
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:03pm, Wednesday, 25'th May 2022
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Affimed Announces Annual General Meeting of Shareholders
10:30am, Tuesday, 24'th May 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
10:30am, Tuesday, 24'th May 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
06:30am, Tuesday, 24'th May 2022
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back thei
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
02:31pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
HEIDELBERG, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back thei
3 Small-Caps That Might Be Acquisition Candidates
08:00pm, Monday, 09'th May 2022 The Motley Fool
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
08:02pm, Friday, 06'th May 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
CORRECTING and REPLACING -- Affimed N.V.
09:21pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American Socie
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)
08:05pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, April 27, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
03:28pm, Monday, 18'th Apr 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back t
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
02:02am, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed Announces Proposed Public Offering of Common Shares
08:03pm, Tuesday, 12'th Apr 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Why Affimed Stock Is Heating Up Today
04:22pm, Monday, 11'th Apr 2022 The Motley Fool
The biotech's experimental blood cancer treatment could be a major advancement.
Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings
04:10pm, Monday, 11'th Apr 2022
Affimed N.V. (NASDAQ: AFMD) provided a data update from its ongoing study of lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.
